Neuropathic pain (NP) is defined as a disorder of the sensorimotor system and is distinctly different from nociceptive pain, which is a consequence of trauma, injury, or inflammation. The main difference between neuropathic and nociceptive pain is the absence of a continuous nociceptive input in neuropathic pain. Although the term neuropathic pain is used to describe a wide range of pain syndromes with varying etiologies, this report focuses on 3 distinct forms of NP: Painful diabetic neuropathy, Postherpetic neuralgia and trigeminal neuralgia. The main classes of drugs used to treat these three neuropathic pain indications include anticonvulsants, antidepressants, opioids and topical treatments. However, despite the availability of multiple pain medications only 50% of patients respond to any given drug and there are numerous the side effects associated particularly with systemically administered drugs, that reduce their tolerability. New treatments will target some key unmet needs in terms of efficacy and tolerability, but opportunities will remain for drugs that can more reliably eradicated NP in targeted patient populations, as well as offering an improved safety profile.

Highlights

Key Questions Answered

• The neuropathic pain market is marked by the presence of a number of unmet needs in current treatments. What are the main unmet needs in this market? Will the drugs under development fulfil the unmet needs of the neuropathic pain market?
• What differences exist in the current disease management across the 3 NP indications, and across the 7 markets?
• What are the views of KOLs on the present and future landscape of the neuropathic pain market?
• Several brands of neuropathic pain drugs are due for patent expiry. How will the patent expiries impact the neuropathic pain therapeutics market?
• The developmental pipeline consists of several novel drugs. Which of these drugs will attain high sales revenues during 2012-2022?

Key Findings

• The main driver for the expansion of the NP market will be the increasing NP incidence due to 2 main reasons: the growing elderly population
• And the increase in the prevalence and diagnosis of type 2 diabetes which will lead to growth of the painful diabetic neuropathy (PDN) market the largest NP segment.
• Additionally, the approval of novel formulations and first-in-class therapies in pipeline for NP that will drive sales in this market
• The greatest barrier to growth in this market will be the fact that the key market leading drugs will go off patent during the forecast period leading to a NP market largely dominated by generics, which raises the barrier to entry for novel drug therapies.

Scope

• Overview of 3 neuropathic pain indications painful diabetic neuropathy, Postherpetic neuralgia and trigeminal neuralgia, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
• Annualized neuropathic pain therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2012 and forecast for 10 years to 2022.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the neuropathic pain therapeutics market.
• Pipeline analysis: focus on mid to late-stage pipeline drugs discussing emerging trends as well as overview of earlier phase drugs.
• Analysis of the current and future market competition in the global neuropathic pain therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
• Develop business strategies by understanding the trends shaping and driving the global neuropathic pain therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global neuropathic pain therapeutics market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Track drug sales in the global neuropathic pain therapeutics market from 2012-2022.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1 Table of Contents 9
1.1 List of Tables16
1.2 List of Figures 23

2 Introduction 26
2.1 Catalyst 26
2.2 Related Reports 26

3 Disease Overview 27
3.1 Clinical Manifestations of Neuropathic Pain - Signs and Symptoms 29
3.1.1 Painful Diabetic Neuropathy 31
3.1.2 Postherpetic Neuralgia 32
3.1.3 Trigeminal Neuralgia 32
3.2 Etiology and Pathophysiology 33
3.2.1 Etiology 34
3.2.2 Pathophysiology 35

4 Epidemiology 43
4.1 Diabetic Neuropathy 43
4.1.1 Disease Background 43
4.1.2 Risk Factors and Comorbidities 44
4.1.3 Global Trends 44
4.1.4 Forecast Methodology 47
4.1.5 Epidemiology Forecast for Diabetic Neuropathy (2012-2022) 57
4.1.6 Discussion 63
4.2 Postherpetic Neuralgia 65
4.2.1 Disease Background 65
4.2.2 Risk Factors and Comorbidities 66
4.2.3 Global Trends 69
4.2.4 Forecast Methodology 75
4.2.5 Epidemiological Forecast for Postherpetic Neuralgia (2012-2022) 84
4.2.6 Discussion 90
4.3 Trigeminal Neuralgia 93
4.3.1 Disease Background 93
4.3.2 Risk Factors and Comorbidities 94
4.3.3 Global Trends 95
4.3.4 Forecast Methodology 97
4.3.5 Epidemiological Forecast for Trigeminal Neuralgia (2012-2022) - Incident Cases 102
4.3.6 Epidemiological Forecast for Trigeminal Neuralgia (2012-2022) - Prevalent Cases 108
4.3.7 Discussion 113

5 Disease Management 117
5.1 Diagnosis and Treatment Overview 117
5.1.1 Diagnosis 117
5.1.2 Treatment Overview and Guidelines 124
5.2 US 134
5.2.1 Diagnosis and Referral 134
5.2.2 Drug Treatment 136
5.3 France 138
5.3.1 Diagnosis and Referral 138
5.3.2 Drug Treatment 140
5.4 Germany 142
5.4.1 Diagnosis and Referral 142
5.4.2 Drug Treatment 143
5.5 Italy 145
5.5.1 Diagnosis and Referral 145
5.5.2 Drug Treatment 147
5.6 Spain 148
5.6.1 Diagnosis and Referral 148
5.6.2 Drug Treatment 150
5.7 UK 151
5.7.1 Diagnosis and Referral 151
5.7.2 Drug Treatment 153
5.8 Japan 155
5.8.1 Diagnosis and Referral 155
5.8.2 Drug Treatment 157

6 Competitive Assessment 159
6.1 Overview 159
6.2 Tricyclic Antidepressants 164
6.2.1 Overview 164
6.2.2 Efficacy 165
6.2.3 Safety 166
6.2.4 Forecast 167
6.3 Calcium Channel Alpha-2-Delta Ligands (Anticonvulsants) 169
6.3.1 Overview 169
6.3.2 Efficacy 170
6.3.3 Safety 171
6.3.4 Forecast 172
6.3.5 Lyrica 174
6.4 Sodium Channel-Blocking Anticonvulsants (TN) 180
6.4.1 Overview 180
6.4.2 Efficacy 181
6.4.3 Safety 181
6.4.4 Forecast 182
6.5 Serotonin-Norepinephrine Reuptake Inhibitors (Antidepressants) 184
6.5.1 Overview 184
6.5.2 Efficacy 184
6.5.3 Safety 185
6.5.4 Forecast 185
6.5.5 Cymbalta 187
6.6 Opioids 191
6.6.1 Overview 191
6.6.2 Efficacy 191
6.6.3 Safety 192
6.6.4 Forecast 193
6.6.5 Nucynta ER/Palexia SR 195
6.7 Topical Therapies 200
6.7.1 Overview 200
6.7.2 Efficacy 201
6.7.3 Safety 201
6.7.4 Forecast 202
6.7.5 Lidoderm/Versatis 204
6.7.6 Qutenza 209

7 Unmet Need and Opportunity 215
7.1 Overview 215
7.2 Physician Knowledge or Awareness 216
7.2.1 Unmet Need 216
7.2.2 Gap Analysis 217
7.2.3 Opportunity 218
7.3 Diagnostic Challenges 218
7.3.1 Unmet Need 218
7.3.2 Gap Analysis 219
7.3.3 Opportunity 219
7.4 Low Treatment Rate and Underdosing of Medications 219
7.4.1 Unmet Need 219
7.4.2 Gap Analysis 221
7.4.3 Opportunity 221
7.5 Unsatisfactory Efficacy and Safety Profiles of Pharmacological Treatments 222
7.5.1 Unmet Need 222
7.5.2 Gap Analysis 223
7.5.3 Opportunity 223
7.6 Elderly Patient Population - Drug Tolerability 224
7.6.1 Unmet Need 224
7.6.2 Gap Analysis 224
7.6.3 Opportunity 225
7.7 Rational or Personalized Therapies 225
7.7.1 Unmet Need 225
7.7.2 Gap Analysis 226
7.7.3 Opportunity 226

8 Pipeline Assessment 228
8.1 Overview 228
8.2 Clinical Trial Mapping 229
8.2.1 Clinical Trials by Patient Population 229
8.3 Promising Drugs in Clinical Development 232
8.3.1 Eslicarbazepine Acetate 234
8.3.2 Topical Clonidine Gel 241
8.3.3 Cebranopadol 245
8.3.4 DS-5565 249
8.3.5 CNV-2197944 253
8.3.6 CNV-1014802 258
8.3.7 Eladur (bupivacaine patch) 262

9 Current and Future Players 267
9.1 Overview 267
9.2 Trends in Corporate Strategy 269
9.3 Company Profiles 270
9.3.1 Pfizer 270
9.3.2 Eli Lilly 272
9.3.3 Grünenthal 274
9.3.4 Endo Health Solutions 277
9.3.5 Janssen Pharmaceuticals 278
9.3.6 Daiichi Sankyo 280
9.3.7 Convergence Pharmaceuticals 282

10 Market Outlook 284
10.1 Global Markets 284
10.1.1 Forecast 284
10.1.2 Drivers and Barriers - Global Issues 294
10.2 United States 296
10.2.1 Forecast 296
10.2.2 Key Events 307
10.2.3 Drivers and Barriers 307
10.3 France 310
10.3.1 Forecast 310
10.3.2 Key Events 320
10.3.3 Drivers and Barriers 320
10.4 Germany 322
10.4.1 Forecast 322
10.4.2 Key Events 332
10.4.3 Drivers and Barriers 332
10.5 Italy 335
10.5.1 Forecast 335
10.5.2 Key Events 345
10.5.3 Drivers and Barriers 345
10.6 Spain 347
10.6.1 Forecast 347
10.6.2 Key Events 357
10.6.3 Drivers and Barriers 357
10.7 United Kingdom 359
10.7.1 Forecast 359
10.7.2 Key Events 369
10.7.3 Drivers and Barriers 369
10.8 Japan 371
10.8.1 Forecast 371
10.8.2 Key Events 381
10.8.3 Drivers and Barriers 381

11 Appendix 384
11.1 Bibliography 384
11.2 Abbreviations 403
11.3 Methodology 409
11.4 Forecasting Methodology 409
11.4.1 Diagnosed PDN, PHN, and TN Patients 409
11.4.2 Percent Drug-Treated Patients 410
11.4.3 Drugs Included In Each Therapeutic Class 410
11.4.4 Launch and Patent Expiry Dates 410
11.4.5 General Pricing Assumptions 411
11.4.6 Individual Drug Assumptions 412
11.4.7 Generic Erosion 416
11.4.8 Pricing of Pipeline Agents 416
11.5 Physicians and Specialists Included in This Study 417
11.6 About the Authors 419
11.6.1 Author 419
11.6.2 Epidemiologists 420
11.6.3 Global Head of Healthcare 421
11.7 About GlobalData 422
11.8 Disclaimer 422

List of Tables

Table 1: Classification of NP Syndromes Based on the Site of Somatosensory Damage 29
Table 2: Signs and Symptoms of NP 30
Table 3: NP Descriptor Terms 43
Table 4: 7MM, Sources of Diabetic Neuropathy Total Prevalence Data 48
Table 5: 7MM, Excluded Sources of Diabetic Neuropathy Total Prevalence Data 51
Table 6: 7MM, Total Prevalent Cases of Diabetic Neuropathy in Diagnosed Diabetics, Both Sexes, Ages ?40 Years, N, 2012-2022 58
Table 7: 7MM, Total Prevalent Cases of Diabetic Neuropathy in Diagnosed Diabetics, Both Sexes, by Age, N, Row (%), 2012 59
Table 8: 7MM, Total Prevalent Cases of Diabetic Neuropathy in Diagnosed Diabetics, by Sex, Ages ?40 Years, N, Row (%), 2012 61
Table 9: 7MM, Sources of PHN Incidence Data 75
Table 10: 7MM, Incident Cases of PHN, Ages ?50 Years, Men and Women, N, 2012-2022 84
Table 11: 7MM, Incident Cases of PHN, by Age, Men and Women, N (Row %), 2012 86
Table 12: 7MM, Incident Cases of PHN, by Sex, Ages ?50 Years, N (Row %), 2012 88
Table 13: Epidemiological Data for TN 96
Table 14: 7MM, Sources of TN Incidence Data 97
Table 15: 7MM, Sources of TN Prevalence Data 97
Table 16: 7MM, Incident Cases of TN, Ages ?50 Years, Men and Women, N, 2012-2022 103
Table 17: 7MM, Incident Cases of TNa, by Age, Men and Women, N, (Row %), 2012 104
Table 18: 7MM, Incident Cases of TN, by Sex, Ages ?50 Years, N (Row %), 2012 106
Table 19: 7MM, Prevalent Cases of TN, Ages ?50 Years, Men and Women, N, 2012-2022 109
Table 20: 7MM, Prevalent Cases of TN, by Age, Men and Women, N, (Row %), 2012 110
Table 21: 7MM, Prevalent Cases of TN, by Sex, Ages ?50 Years, N (Row %), 2012 112
Table 22: Screening Tools for NP 118
Table 23: NP-Related Signs and Symptoms 120
Table 24: Treatment Guidelines for NP 125
Table 25: Recommended Drug Therapies for NP Conditions by Line of Therapy 131
Table 26: Most Prescribed Drugs for NP by Indication and Line of Therapy in the Global Markets, 2012 133
Table 27: US - NP Diagnosis and Referral Metrics 135
Table 28: US - NP Treatment Metrics 138
Table 29: France - NP Diagnosis and Referral Metrics 140
Table 30: France - NP Treatment Metrics 141
Table 31: Germany - NP Diagnosis and Referral Metrics 143
Table 32: Germany - NP Treatment Metrics 145
Table 33: Italy - NP Diagnosis and Referral Metrics 146
Table 34: Italy - NP Treatment Metrics 148
Table 35: Spain - NP Diagnosis and Referral Metrics 149
Table 36: Spain - NP Treatment Metrics 151
Table 37: UK - NP Diagnosis and Referral Metrics 153
Table 38: UK - NP Treatment Metrics 155
Table 39: Japan - NP Diagnosis and Referral Metrics 156
Table 40: Japan - NP Treatment Metrics 158
Table 41: NNT and NNH for Classes of Oral Drugs used in NP Treatment, 2013 161
Table 42: Select Products Used for NP Treatment, 2013 163
Table 43: Global Sales Forecasts ($m) for TCAs, 2012-2022 168
Table 44: Global Sales Forecasts ($m) for Calcium Channel Alpha-2-Delta Ligands, 2012-2022 173
Table 45: Product Profile - Lyrica 175
Table 46: Lyrica SWOT Analysis, 2013 177
Table 47: Global Sales Forecasts ($m) for Lyrica, 2012-2022 179
Table 48: Global Sales Forecasts ($m) for Sodium Channel-Blocking Anticonvulsants, 2012-2022 183
Table 49: Global Sales Forecasts ($m) for SNRIs, 2012-2022 186
Table 50: Product Profile - Cymbalta 187
Table 51: Cymbalta SWOT Analysis, 2013 189
Table 52: Global Sales Forecasts ($m) for Cymbalta, 2012-2022 190
Table 53: Global Sales Forecasts ($m) for Opioids, 2012-2022 194
Table 54: Product Profile - Nucynta ER/Palexia SR 196
Table 55: Nucynta ER/Palexia SR SWOT Analysis, 2013 197
Table 56: Global Sales Forecasts ($m) for Nucynta ER/Palexia SR, 2012-2022 199
Table 57: Global Sales Forecasts ($m) for Topical Therapies, 2012-2022 203
Table 58: Product Profile - Lidoderm/Versatis 205
Table 59: Lidoderm/Versatis SWOT Analysis, 2013 206
Table 60: Global Sales Forecasts ($m) for Lidoderm/Versatis, 2012-2022 208
Table 61: Product Profile - Qutenza 210
Table 62: Qutenza SWOT Analysis, 2013 212
Table 63: Global Sales Forecasts ($m) for Qutenza, 2012-2022 214
Table 64: Unmet Need and Opportunity in NP 216
Table 65: NP - Promising Drugs in Clinical Development 232
Table 66: Comparison of Drugs in Development for NP, 2014 233
Table 67: Product Profile - Eslicarbazepine Acetate 235
Table 68: Phase II: Efficacy of Eslicarbazepine Acetate in PHN 236
Table 69: Phase II: Efficacy of Eslicarbazepine Acetate in PDN 236
Table 70: Eslicarbazepine Acetate SWOT Analysis, 2013 238
Table 71: Global Sales Forecasts ($m) for Eslicarbazepine Acetate, 2012-2022 240
Table 72: Product Profile - Topical Clonidine Gel 242
Table 73: Topical Clonidine Gel SWOT Analysis, 2013 244
Table 74: Global Sales Forecasts ($) for Topical Clonidine Gel, 2012-2022 245
Table 75: Product Profile - Cebranopadol 246
Table 76: Cebranopadol SWOT Analysis, 2013 248
Table 77: Global Sales Forecasts ($) for Cebranopadol, 2012-2022 249
Table 78: Product Profile - DS-5565 250
Table 79: DS-5565 SWOT Analysis, 2013 252
Table 80: Global Sales Forecasts ($) for DS-5565, 2012-2022 253
Table 81: Product Profile - CNV-2197944 254
Table 82: CNV-2197944 SWOT Analysis, 2013 256
Table 83: Global Sales Forecasts ($m) for CNV-2197944, 2012-2022 257
Table 84: Product Profile - CNV1014802 259
Table 85: CNV-1014802 SWOT Analysis, 2013 261
Table 86: Global Sales Forecasts ($) for CNV-1014802, 2012-2022 262
Table 87: Product Profile - Eladur 263
Table 88: Eladur SWOT Analysis, 2013 265
Table 89: Global Sales Forecasts ($) for Eladur, 2012-2022 266
Table 90: Key Companies in the NP Market, 2014 268
Table 91: Pfizer's NP Portfolio Assessment, 2014 271
Table 92: Pfizer SWOT Analysis, 2013 272
Table 93: Eli Lilly's NP Portfolio Assessment, 2013 273
Table 94: Eli Lilly SWOT Analysis, 2013 274
Table 95: Grünenthal's NP Portfolio Assessment, 2013 276
Table 96: Grünenthal SWOT Analysis, 2013 276
Table 97: Endo Health Solutions' NP Portfolio Assessment, 2013 278
Table 98: Endo Health Solutions SWOT Analysis, 2013 278
Table 99: Janssen Pharmaceuticals' NP Portfolio Assessment, 2013 279
Table 100: Janssen Pharmaceuticals SWOT Analysis, 2013 280
Table 101: Daiichi Sankyo's NP Portfolio Assessment, 2013 281
Table 102: Daiichi Sankyo SWOT Analysis, 2013 282
Table 103: Convergence Pharmaceuticals' NP Portfolio Assessment, 2013 283
Table 104: Convergence Pharmaceuticals SWOT Analysis, 2013 283
Table 105: Global Sales Forecasts ($) for NP, 2012-2022 286
Table 106: Global Sales Forecasts ($) for PDN, 2012-2022 288
Table 107: Global Sales Forecasts ($) for PHN, 2012-2022 290
Table 108: Global Sales Forecasts ($) for TN, 2012-2022 292
Table 109: NP Market - Drivers and Barriers, 2012-2022 294
Table 110: Sales Forecasts ($) for NP in the United States, 2012-2022 298
Table 111: Sales Forecasts ($) for PDN in the United States, 2012-2022 301
Table 112: Sales Forecasts ($) for PHN in the United States, 2012-2022 303
Table 113: Sales Forecasts ($) for TN in the United States, 2012-2022 305
Table 114: Key Events Impacting Sales for NP in the United States, 2012-2022 307
Table 115: NP Market - Drivers and Barriers in the United States, 2012-2022 307
Table 116: Sales Forecasts ($) for NP in France, 2012-2022 312
Table 117: Sales Forecasts ($) for PDN in France, 2012-2022 314
Table 118: Sales Forecasts ($) for PHN in France, 2012-2022 316
Table 119: Sales Forecasts ($) for TN in France, 2012-2022 318
Table 120: Key Events Impacting Sales for NP in France, 2012-2022 320
Table 121: NP Market- Drivers and Barriers in France, 2012-2022 320
Table 122: Sales Forecasts ($) for NP in Germany, 2012-2022 324
Table 123: Sales Forecasts ($) for PDN in Germany, 2012-2022 326
Table 124: Sales Forecasts ($) for PHN in Germany, 2012-2022 328
Table 125: Sales Forecasts ($) for TN in Germany, 2012-2022 330
Table 126: Key Events Impacting Sales for NP in Germany, 2012-2022 332
Table 127: NP Market - Drivers and Barriers in Germany, 2012-2022 332
Table 128: Sales Forecasts ($) for NP in Italy, 2012-2022 337
Table 129: Sales Forecasts ($) for PDN in Italy, 2012-2022 339
Table 130: Sales Forecasts ($) for PHN in Italy, 2012-2022 341
Table 131: Sales Forecasts ($) for TN in Italy, 2012-2022 343
Table 132: Key Events Impacting Sales for NP in Italy, 2012-2022 345
Table 133: NP Market- Drivers and Barriers in Italy, 2012-2022 345
Table 134: Sales Forecasts ($) for NP in Spain, 2012-2022 349
Table 135: Sales Forecasts ($) for PDN in Spain, 2012-2022 351
Table 136: Sales Forecasts ($) for PHN in Spain, 2012-2022 353
Table 137: Sales Forecasts ($) for TN in Spain, 2012-2022 355
Table 138: Key Events Impacting Sales for NP in Spain, 2012-2022 357
Table 139: NP Market- Drivers and Barriers in Spain, 2012-2022 357
Table 140: Sales Forecasts ($) for NP in the UK, 2012-2022 361
Table 141: Sales Forecasts ($) for PDN in the UK, 2012-2022 363
Table 142: Sales Forecasts ($) for PHN in the UK, 2012-2022 365
Table 143: Sales Forecasts ($) for TN in the UK, 2012-2022 367
Table 144: Key Events Impacting Sales for NP in the UK, 2012-2022 369
Table 145: NP Market - Drivers and Barriers in the UK, 2012-2022 369
Table 146: Sales Forecasts ($) for NP in Japan, 2012-2022 373
Table 147: Sales Forecasts ($) for PDN in Japan, 2012-2022 375
Table 148: Sales Forecasts ($) for PHN in Japan, 2012-2022 377
Table 149: Sales Forecasts ($) for TN in Japan, 2012-2022 379
Table 150: Key Events Impacting Sales for NP in Japan, 2012-2022 381
Table 151: NP Market - Drivers and Barriers in Japan, 2012-2022 381
Table 152: Key Launch Dates 410
Table 153: Key Patent/Exclusivity Expiries 411

List of Figures

Figure 1: Nociceptive Versus Neuropathic Pain 28
Figure 2: Etiology and Pathophysiology of NP 33
Figure 3: Pain Pathway - Somatosensory System 36
Figure 4: Pathophysiological Mechanisms of NP at Different Levels of the Nervous System 40
Figure 5: Pathophysiological Targets of NP Drugs 41
Figure 6: 7MM, Total Prevalent Cases of Diabetic Neuropathy in Diagnosed Diabetics, Both Sexes, Ages ?40 Years, N, 2012-2022 58
Figure 7: 7MM, Total Prevalent Cases of Diabetic Neuropathy in Diagnosed Diabetics, Both Sexes, by Age, N, 2012 60
Figure 8: 7MM, Total Prevalent Cases of Diabetic Neuropathy in Diagnosed Diabetics, by Sex, Ages ?40 Years, N, 2012 61
Figure 9: 7MM, Comorbid Hypertension in Diabetic Neuropathy Cases (N), Both Sexes, Ages ?40, 2012 62
Figure 10: 7MM, Incident Cases of PHN, Ages ?50 Years, Men and Women, N, 2012-2022 85
Figure 11: 7MM, Incident Cases of PHN, by Age, Men and Women, N, 2012 87
Figure 12: 7MM, Incident Cases of PHN, by Sex, Ages ?50 Years, N, 2012 88
Figure 13: 7MM, Age-Standardized Incidence of PHN (per 1,000 Population), Ages ?50 Years, Men and Women, 2012 90
Figure 14: 7MM, Incident Cases of TN, Ages ?50 Years, Men and Women, N, 2012-2022 103
Figure 15: 7MM, Incident Cases of TN, by Age, Men and Women, N, 2012 105
Figure 16: 7MM, Incident Cases of TN, by Sex, Ages ?50 Years, N, 2012 106
Figure 17: 7MM, Age-Standardized Incidence of TN (per 100,000 Population), Ages ?50 Years, Men and Women, 2012 108
Figure 18: 7MM, Prevalent Cases of TN, Ages ?50 Years, Men and Women, N, 2012-2022 109
Figure 19: 7MM, Prevalent Cases of TN, by Age, Men and Women, N, 2012 111
Figure 20: 7MM, Prevalent Cases of TN, by Sex, Ages ?50 Years, N, 2012 112
Figure 21: NeuSPIG Diagnostic Certainty Algorithm for NP 121
Figure 22: General Treatment Algorithm for NP 130
Figure 23: NP Therapeutics - Number of Phase II and III Clinical Trials in Each Indication in the 7MM 230
Figure 24: Competitive Assessment of Mid-to-Late Stage Pipeline Agents in NP, 2012-2022 234
Figure 25: Company Portfolio Gap Analysis in NP, 2012-2022 269
Figure 26: Global Sales for NP by Region, 2012-2022 287
Figure 27: Global Sales for PDN by Drug Class, 2012-2022 289
Figure 28: Global Sales for PHN by Drug Class, 2012-2022 291
Figure 29: Global Sales for TN by Drug Class, 2012-2022 293
Figure 30: Sales for NP in the United States by Drug Class, 2012-2022 300
Figure 31: Sales for PDN in the United States by Drug Class, 2012-2022 302
Figure 32: Sales for PHN in the United States by Drug Class, 2012-2022 304
Figure 33: Sales for TN in the United States by Drug Class, 2012-2022 306
Figure 34: Sales for NP in France by Drug Class, 2012-2022 313
Figure 35: Sales for PDN in France by Drug Class, 2012-2022 315
Figure 36: Sales for PHN in France by Drug Class, 2012-2022 317
Figure 37: Sales for TN in France by Drug Class, 2012-2022 319
Figure 38: Sales for NP in Germany by Drug Class, 2012-2022 325
Figure 39: Sales for PDN in Germany by Drug Class, 2012-2022 327
Figure 40: Sales for PHN in Germany by Drug Class, 2012-2022 329
Figure 41: Sales for TN in Germany by Drug Class, 2012-2022 331
Figure 42: Sales for NP in Italy by Drug Class, 2012-2022 338
Figure 43: Sales for PDN in Italy by Drug Class, 2012-2022 340
Figure 44: Sales for PHN in Italy by Drug Class, 2012-2022 342
Figure 45: Sales for TN in Italy by Drug Class, 2012-2022 344
Figure 46: Sales for NP in Spain by Drug Class, 2012-2022 350
Figure 47: Sales for PDN in Spain by Drug Class, 2012-2022 352
Figure 48: Sales for PHN in Spain by Drug Class, 2012-2022 354
Figure 49: Sales for TN in Spain by Drug Class, 2012-2022 356
Figure 50: Sales for NP in the UK by Drug Class, 2012-2022 362
Figure 51: Sales for PDN in the UK by Drug Class, 2012-2022 364
Figure 52: Sales for PHN in the UK by Drug Class, 2012-2022 366
Figure 53: Sales for TN in the UK by Drug Class, 2012-2022 368
Figure 54: Sales for NP in Japan by Drug Class, 2012-2022 374
Figure 55: Sales for PDN in Japan by Drug Class, 2012-2022 376
Figure 56: Sales for PHN in Japan by Drug Class, 2012-2022 378
Figure 57: Sales for TN in Japan by Drug Class, 2012-2022 380